Benefits
Appetite Control / Reduced Food Intake
A 2024 Nexira animal (in vivo) study reported a 47% reduction in food intake at a 3 g/day human-equivalent dose over 4 weeks. This is a preclinical result that has not been confirmed in humans. Proposed mechanism: slowing of gastric emptying to prolong fullness.
Rapid Satiety Onset
In simulated ingestion conditions, Carolean™ achieves 70% of maximum viscosity within 15 minutes of ingestion — faster than recognized market satiety ingredients. This reflects an in vitro viscosity measurement in simulated conditions, not a demonstrated human satiety comparison.
Gastric Emptying Delay
The same 2024 Nexira animal study reported slowing of gastric emptying in single-dose and prolonged-use scenarios. Human confirmation is not yet available.
Synergistic Action
Carob (galactomannan) and Nopal (soluble fiber/mucilage) work synergistically — different fiber types with complementary water-binding and gel-forming properties create enhanced satiety effect vs either alone.
Weight Management Adjunct
Reduced food intake supports caloric deficit; useful adjunct in comprehensive weight management. Effects via appetite mechanism rather than metabolism.
Mechanism of action
Gastric Emptying Delay
Soluble fibers from carob and nopal create gel-like matrix in stomach that slows gastric emptying — prolongs feeling of fullness, reduces subsequent food intake. Foundation for appetite control.
Carob Galactomannan
Carob (locust bean gum) provides galactomannan — soluble fiber with strong water-binding and gel-forming properties. Mannose:galactose ratio of 4:1.
Nopal Soluble Fiber and Mucilage
Nopal provides additional soluble fiber, mucilage, and pectin compounds — complementary to carob with different viscosity profile.
Patent-Pending Synergistic Formulation
Specific ratios and processing developed by Nexira to optimize satiety kinetics — patent-pending status reflects novel formulation approach. Effects greater than additive of individual components.
Clinical trials
In vivo study of Carolean™ at 3 g/day equivalent for 4 weeks on appetite, gastric emptying, and food intake.
Animal in vivo model.
Significant slowing of gastric emptying in single and prolonged use; 47% average reduction in food intake. Suggested a dose-related effect in this preclinical animal model; not established in humans.
Simulated ingestion conditions (temperature, pH) measuring viscosity development over time.
In vitro / simulated GI conditions.
70% of maximum viscosity reached within 15 minutes — an in vitro viscosity observation, not an established human satiety advantage.